Diabetes Combination Studies Leave Market Challenges Unresolved

Novo Nordisk and Sanofi's trials were intended to satisfy FDA's combination product rule, but sponsors have not addressed some important clinical questions around use of the basal insulin/GLP-1 agonist products.